Design Therapeutics, Inc. — Director's Dealing 2021

Apr 2, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Design Therapeutics, Inc. (DSGN)
CIK: 0001807120
Period of Report: 2020-03-30

Reporting Person: William Arsani (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-03-30	Common Stock	C	1217627	—	Acquired	1217627	Indirect
2021-03-30	Common Stock	C	814874	—	Acquired	2032501	Indirect
2021-03-30	Common Stock	P	700000	$20.00	Acquired	2732501	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-30	Series B Preferred Stock	$	C	1984733	Disposed		Common Stock (1217627)	Indirect
2021-03-30	Series B Preferred Stock	$	C	1328245	Disposed		Common Stock (814874)	Indirect

Footnotes

F1: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date.

F2: The Reporting Person is a managing member of Logos Opportunities Fund II, L.P. and Logos SPV 1 LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F3: Logos Global Management LP ("LGM") is the investment adviser of private funds, including Logos Global Master Fund LP (the "Fund"). Logos GP LLC ("Fund GP") is the general partner of the Fund. The Reporting Person is the Manager of Fund GP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of Reporting Person's pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.